bioRxivBioinformaticsPreprint
Active and Allosteric Site Binding MOLECULAR MECHANICS-QUANTUM MECHANICS studies of STEVIOSIDE Derivative in PCSK9 Protein Intended to provide a safe Antilipidemic agent
N Irfan, Prakash Vaithyanathan, Harishchander AnandaramiD, S Mohammed ZaidhiD, S. Priya Varshini, Ayarivan PuratchikodyiD
Abstract
Interaction of low-density lipoprotein receptors with proprotein convertase subtilisin/ kexin type 9 (PCSK9) plays a vital role in causing atherosclerosis. It is the hidden precursor of clinical myocardial infarction (MI), stroke, CVD and estimates 60% of deaths worldwide. The current need is to design small molecules to prevent the interaction between PCSK9 with LDL receptors. This study aims to evaluate the PCSK9 antagonistic effect of a derivative of Stevioside (also referred as Methylidene tetracyclo derivative) and atorvastatin. Also, a comparative study was performed to analyze the binding interaction of molecules inside the active and allosteric sites of PCSK9. The RCSB downloaded protein 7S5H and above said ligands were optimized to the local minima energy level and docked inside the active and allosteric sites. The stability of non-bonded interaction of complex was analyzed using Desmond MD simulation studies. The results of docking showed that the Methylidene tetracyclo molecule possesses a two-fold higher affinity of -10.159 kcal/mol in the active site and -10.824 kcal/mol in the allosteric site. The Phe377 amino acid made the Methylidene tetracyclo molecule orient inside the active site. Nine H-bonds with 5 amino acids of allosteric site increase the binding affinity compared to Atorvastatin. The MD simulation studies exposed that the nonbonded interaction of Methylidene tetracyclo molecule was stable throughout 100ns. This confirms the Methylidene tetracyclo molecule will be the better hit as well as the lead molecule to inhibit PCSK9 protein.
- Citations
- 2
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Molecular and Quantum Mechanical Studies of Interaction Between Tetrahydrocurcumin Derivative and PCSK9 Protein to Provide a Basis for an Oral Pill to Remove Bad Cholesterol
Prakash Vaithyanathan·bioRxiv·Jul 4, 2023
- A transient amphipathic helix in the PCSK9 prodomain facilitates low-density lipoprotein binding
Samantha K. Sarkar, Alexander C. Y. Foo, … Thomas A. Lagace·Journal of Biological ChemistryPeer-reviewed·Jan 16, 2020
- Molecular interactions of PCSK9 with an inhibitory nanobody, CAP1 and HLA-C: functional regulation of LDLR levels
Carole Fruchart‐Gaillard, Ali Ben Djoudi Ouadda, … Nabil Georges Seidah·Molecular MetabolismPeer-reviewed·Dec 22, 2022
- Structural Dynamics of LDL Receptor Interactions with E498A and R499G Variants of PCSK9
Nur Alya Amirah Azhar, Yung-An Chua, … Siti Azma Jusoh·Journal of Molecular ModelingPeer-reviewed·May 19, 2025
- Pyrroloquinoline Quinone inhibits PCSK9, augments LDLR recycling and enhances the effect of atorvastatin
K. V. Devasani, A. Majumdar, … R. Kaul·bioRxiv·Mar 20, 2022
- Unraveling the Potential of Hypericin: A Novel Approach to Targeting PCSK9 Mutations in Cholesterol Management
Ivan Vito Ferrari·bioRxiv·Oct 6, 2024